Myelodysplastic Syndromes (MDS)

Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia

Original Publication Date

November 18, 2025

Article Source

External Web Content

Abstract Somatic mutations in hematopoietic stem/progenitor cells (HSPCs) can lead to clonal hematopoiesis of indeterminate potential (CHIP) and progression to myelodysplastic syndromes (MDS). Using single-cell and anatomical profiling of a large cohort of human bone marrow (BM)…

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

Original Publication Date

November 5, 2025

Article Source

External Web Content

Key Points Ivosidenib, venetoclax ± azacitidine either rapidly selects evolved, resistant leukemic clones or eradicates leukemic clones. Resistant clones express RNA signatures of stemness, branched-chain amino acid metabolism, and menin targets. Subjects:Myeloid Neoplasia…

Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry

Read more about Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry

Infections are an important cause of morbidity and mortality in patients with lower-risk myelodysplastic syndromes myelodysplastic syndromes:

Optimal timing of allogeneic hematopoietic stem cell transplant in MDS

Read more about Optimal timing of allogeneic hematopoietic stem cell transplant in MDS

Myelodysplastic neoplasms (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis hematopoiesis: (hi-mat-uh-poy-EE-suss) The process of making blood cells in